You prescribe drugs every day. But do you understand how they're priced?

Most physicians don't. Medical school taught us mechanism of action, not pharmacy economics. And that knowledge gap has consequences.

Every time a patient tells you they can't afford their medication, you're witnessing the downstream effect of a supply chain you were never trained to understand. Every prior authorization you write, every formulary exception you request, every awkward conversation about cost—these are symptoms of a system that operates in the shadows.

This guide pulls back the curtain.

Inside, you'll learn how drugs move from manufacturing facilities to your patients' medicine cabinets. You'll understand why a generic medication that costs $20 to make carries a $500 copay. You'll see where the money flows, who profits, and why the incentives are misaligned with patient care.

More importantly, you'll walk away with practical tools: scripts for cost conversations, strategies for navigating formularies, templates for writing prior authorization appeals that actually work, and resources you can hand to patients who can't afford their prescriptions.

Alrighty, let’s get started on this adventure. Buckle up.

The drug supply chain sounds simple: make a drug, ship it, dispense it.

It's not.

Between the factory that produces your patient's metformin and the pharmacy where they pick it up, at least six entities touch that bottle. Each one negotiates, each one takes a cut, and each one adds complexity that ultimately shows up as cost.

Here's how it works.

1. Drug Manufacturers

These are the pharmaceutical companies—Pfizer, Merck, Eli Lilly, and hundreds of others. They develop drugs, get FDA approval, manufacture at scale, and set the list price.

That list price is critical. It's the starting point for every negotiation downstream. And it's often wildly disconnected from manufacturing cost.

Manufacturers make drugs and negotiate with every other player in the chain to ensure their products get prescribed. They offer rebates to PBMs, discounts to wholesalers, and patient assistance programs to offset high copays.

Their goal: volume. The more prescriptions written, the more revenue generated.

2. Wholesalers

Wholesalers are the middlemen between manufacturers and pharmacies. Think McKesson, AmerisourceBergen, Cardinal Health—the big three that control about 90% of U.S. drug distribution.

They buy drugs in bulk from manufacturers and distribute them to pharmacies, hospitals, and clinics. They manage inventory, handle logistics, and ensure medications are available when needed.

Wholesalers operate on thin margins—typically 2-3% markup. Their profit comes from scale and efficiency, not from jacking up prices.

Most of the pricing chaos happens elsewhere.

3. Pharmacy Benefit Managers (PBMs)

PBMs are the power brokers. They don't manufacture drugs or dispense them, but they control which drugs get covered, at what tier, and at what cost.

Insurers hire PBMs to manage prescription benefits. PBMs negotiate rebates with manufacturers, build formularies, set reimbursement rates for pharmacies, and adjudicate every claim in real time.

The big three—CVS Caremark, Express Scripts, and OptumRx—control roughly 80% of U.S. prescriptions.

PBMs, however, profit from rebates that are tied to a drug's list price. Higher list price means bigger rebate. So PBMs have an incentive to favor expensive drugs over cheaper alternatives—as long as the rebate is fat enough.

We'll dig deeper into PBMs in Part 2. For now, just know: they sit at the center of the cost problem.

4. Pharmacies

Pharmacies dispense medications to patients. Chains like CVS and Walgreens dominate, but independent pharmacies still fill about 35% of prescriptions.

Pharmacies get reimbursed by PBMs based on pre-negotiated rates—often tied to opaque benchmarks like Average Wholesale Price (AWP) or Maximum Allowable Cost (MAC).

The reimbursement often barely covers the pharmacy's cost. Many independents are underwater on generic prescriptions, which is why they push higher-margin services like vaccines and supplements.

Pharmacies are squeezed between PBMs setting low reimbursement rates and patients demanding lower copays. It's a losing position.

5. Insurers (Health Plans)

Insurers design drug benefits, set copays and deductibles, and ultimately pay for prescriptions (minus the patient's out-of-pocket cost).

Most insurers outsource the heavy lifting to PBMs. The insurer sets budget targets—"keep drug spend under X"—and the PBM delivers by negotiating rebates and managing utilization.

Insurers receive a portion of the rebates negotiated by their PBM. Those rebates lower the plan's net cost, but they rarely reduce patient copays at the point of sale.

That's why your patient's $500 copay feels outrageous even though the insurer's actual cost might be $100 after rebates.

6. Patients (You and Your Patients)

Patients are the end users—and the ones who get squeezed hardest.

They see the list price at the pharmacy counter. They pay copays based on formulary tiers that they didn't choose. They face prior authorization delays for medications their doctor prescribed. And they're often unaware that paying cash might be cheaper than using insurance.

Patients have the least power and the least transparency. They're the last to know and the first to pay.

Here's the key insight: drugs and money move in opposite directions.

Drugs flow forward:

Manufacturer → Wholesaler → Pharmacy → Patient

Money flows backward:

Patient → Pharmacy → PBM → Insurer (and rebates flow from Manufacturer → PBM → Insurer)

But the money doesn't flow cleanly. It loops, splits, and gets siphoned at every junction.

The result: a system where everyone claims they're saving money, but drug spending keeps climbing and patients keep paying more.

When you write that prescription, you're dropping your patient into this six-entity supply chain with misaligned incentives, opaque pricing, and zero transparency.

When a patient tells you they can't afford their medication, it's not always because the drug is expensive to make. It's because the system monetizes complexity.

Understanding this chain gives you power. You'll know when to check cash prices, when to request a formulary exception, and when to send a patient to Cost Plus Drugs instead of their insurance pharmacy.

You can't fix the supply chain. But you can help your patients navigate it.

Let's move to Part 2, where we break down why U.S. drug prices are so high—and why the PBM model is at the center of the problem.

Purchase the guide to access all parts!